is there still a glp-1 shortage The drug over. What's next for the compounders? Hims & Hers stock falls

Your health journey should be an ongoing process to find which course of action works best for your lifestyle and body

We would love to hear from you

BaldisseraFGHolstJJKnuhtsenSHilstedLNielsenO.V

Nature 535, 376381

Both basic research and clinical studies have suggested that GLP-1 receptor agonists may have the potential to improve stroke recurrence and prognosis. LAMP was a multicenter, randomized controlled, prospective trial designed to evaluate the efficacy and safety of liraglutide (Victoza/Saxenda, Novo Nordisk) for the prevention of recurrent stroke after minor ischemic stroke or high-risk TIA in patients with diabetes